Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio

Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6...